Bio Pharma Dive

FEBRUARY 29, 2024

The unusual deal will see one of the investment firm’s startups work with Gilead to expand the cancer drug’s label, with Abingworth receiving payment if successful.

Development 164

Development Drugs 164

Pharmaceutical Technology

DECEMBER 27, 2023

The deal is worth approximately $1.2bn in combined upfront and potential contingent value payments and is expected to close in Q1 2024.

246

246

Pharmaceutical Technology

JUNE 23, 2023

Psylo and Daiichi Sankyo have signed a sponsored research deal to advance the development of non-hallucinogenic psychiatric therapies.

Research 299

Research Development 299

Bio Pharma Dive

MARCH 25, 2024

Cardior’s therapy is currently in mid-stage testing and should the deal close, Novo plans to start another Phase 2 trial in heart failure.

Drugs 156

Drugs Trials 156

Bio Pharma Dive

FEBRUARY 1, 2024

The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.

183

183

Pharmaceutical Technology

SEPTEMBER 21, 2023

Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.

Development 246

Development Medicine 246

Pharmaceutical Technology

NOVEMBER 29, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Under the deal, Neogene will receive $200m in initial payment at closing, as well as up to $120m in contingent milestones-based and non-contingent payments.

Gene Therapy 279

Gene Therapy Gene Development Manufacturing 279

Bio Pharma Dive

APRIL 5, 2023

The deal hands Ginkgo technology for discovering and engineering capsids — the outer shell that protects the helpful genetic material in gene therapies.

Gene Therapy 254

Gene Therapy Gene Engineer Genetics 254

Bio Pharma Dive

NOVEMBER 3, 2022

With public offerings difficult to pull off, Artiva is focusing its energy on a cancer drug deal with the German biotech.

Drugs 343

Drugs 343

Pharmaceutical Technology

DECEMBER 20, 2023

Neurogene has concluded its merger deal with Neoleukin Therapeutics to develop genetic therapies for complex neurological ailments.

Genetics 130

Genetics Development 130

Pharmaceutical Technology

NOVEMBER 28, 2022

The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. According to the deal, C4XD is entitled to get up to $16m in pre-clinical milestone payments before the commencement of the first clinical trial. . Additionally, AstraZeneca will make a potential payment of $385.8m

Development 264

Development Gene Expression Licensing Licensing 264

Bio Pharma Dive

AUGUST 24, 2023

The deal, worth up to $500 million, is a bet by the drug rights dealmaker on the uncertain commercial prospects of Ferring's gene therapy Adstiladrin.

Gene Therapy 244

Gene Therapy Gene Drugs 244

Bio Pharma Dive

APRIL 25, 2024

“With each passing year, we're more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.

Gene Editing 288

Gene Editing Gene Genetics Medicine 288

Bio Pharma Dive

JANUARY 2, 2024

The deal builds on an existing alliance and includes tools Novartis will use in gene therapies for Huntington’s disease and spinal muscular atrophy.

Gene Therapy 164

Gene Therapy Gene 164

Bio Pharma Dive

NOVEMBER 21, 2023

In a deal worth up to $610 million, Merck will gain a pipeline of neuroscience and rare disease programs from a startup it previously backed.

177

177

Pharmaceutical Technology

JUNE 8, 2023

Each week, Pharmaceutical Technology’s editors select a deal that illustrates the themes driving change in our sector. The deal may not always be the largest in value, or the highest profile. But it will tell us where the leading companies are focusing their efforts, and why.

Marketing 259

Marketing Drugs 259

Pharmaceutical Technology

JULY 26, 2023

In the global pharmaceutical industry, there were 92 private equity deals announced in Q2 2023, worth a total value of $17.3bn, according to GlobalData's Deals Database.

130

130

Pharmaceutical Technology

MARCH 17, 2023

Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health. Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin).

Hormones 263

Hormones Licensing Licensing Medicine 263

Bio Pharma Dive

DECEMBER 14, 2023

The deal, struck after Editas was awarded ownership of a key patent for the landmark gene editing technology, could be the first of many like it.

Gene Editing 156

Gene Editing Gene 156

Pharmaceutical Technology

MARCH 28, 2024

Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system as the top three therapy areas by total deal value with a combined $21bn over the past five years.

Licensing 130

Licensing Licensing Drugs 130

pharmaphorum

APRIL 22, 2024

Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies by reserving exclusive capacity wt contract manufacturer Cellares in $380m deal

Contract Manufacturing 102

Contract Manufacturing Manufacturing 102

Pharmaceutical Technology

DECEMBER 4, 2023

The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.

Antibody 162

Antibody Drugs Development 162

Bio Pharma Dive

JULY 5, 2022

An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.

Engineer 319

Engineer Antibody Drugs 319

Pharmaceutical Technology

NOVEMBER 21, 2023

Zevra Therapeutics has concluded the takeover of complete outstanding shares of Acer Therapeutics in a deal valued at $91m.

130

130

Pharmaceutical Technology

JULY 31, 2023

In Germany pharmaceutical industry, there were 3 private equity deals announced in Q2 2023, worth a total value of $271.4m, according to GlobalData's Deals Database.

130

130

Bio Pharma Dive

FEBRUARY 26, 2024

The deal would mark a retreat from public markets for the once notable biotech, which was forced to cut staff last year to save cash after trial setbacks.

Trials 156

Trials Marketing 156

Pharmaceutical Technology

OCTOBER 7, 2022

As per the deal, Sanofi will extend commercial resources in the US and Provention will pay for the former’s field force-associated expenses linked to teplizumab’s commercialisation. The post Provention and Sanofi enter deal to launch teplizumab for type 1 diabetes appeared first on Pharmaceutical Technology.

FDA Approval 299

FDA Approval Licensing Licensing Antibody 299

Bio Pharma Dive

NOVEMBER 19, 2020

The deal, which has Pfizer paying as much as $70 million, is the latest in a series of moves by big pharma companies to forge a stronger position in the world's second-largest drug market.

Pharma Companies 364

Pharma Companies Marketing Drugs 364

Fierce Pharma

APRIL 7, 2024

Last year closed with a flurry of big-money biopharma deals. Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.

Marketing 95

Marketing Research 95

Bio Pharma Dive

OCTOBER 6, 2021

Now, a Pfizer deal on new technology gives investors hope. Voyager Therapeutics recently scrapped much of its pipeline and replaced top executives.

Gene Therapy 330

Gene Therapy Gene Development 330

pharmaphorum

APRIL 2, 2024

The deal, which has a top-end value of $900 million including $90 million in near-term payments, focuses on STRO-003, a preclinical-stage ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1).

Licensing 104

Licensing Licensing Antibody Drugs 104

Pharmaceutical Technology

DECEMBER 11, 2023

Nona Biosciences has entered a partnership deal with biopharmaceutical company Evive Biotech to discover antibodies.

Antibody 130

Antibody 130

Bio Pharma Dive

MARCH 10, 2022

Arena Pharmaceuticals expects its $7 billion sale to Pfizer to close Friday, ending a slightly protracted regulatory review that raised questions about whether the deal would be cleared as anticipated.

Sales 294

Sales 294

Pharmaceutical Technology

NOVEMBER 15, 2023

deal for the discovery and development of drug candidates. Autifony Therapeutics and Jazz Pharmaceuticals have signed a $770.5m

Development 130

Development Drugs 130

Pharmaceutical Technology

JULY 24, 2023

In the Middle East and Africa pharmaceutical industry, there were 4 private equity deals announced in Q2 2023, worth a total value of $49.6m, according to GlobalData's Deals Database.

130

130

pharmaphorum

FEBRUARY 28, 2024

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Immunotherapeutics.

Protein 112

Protein Antibody Drugs Development 112

Pharmaceutical Technology

JULY 6, 2023

F-star Therapeutics and Takeda have signed a strategic discovery partnership and licence deal to develop multi-specific immunotherapies.

Development 130

Development Antibody 130